Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
October 2023 in “Journal of cystic fibrosis” 2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.